Molecular follow-up of patients with promyelocytic leukaemia treated with alltrans retinoic acid

Clinical and Laboratory Haematology

Volumn 20, Issue 3, 1998, Pages 173-176

  Ruiz Arguelles G J ^a,b   Garces Eisele J ^b   Ruiz Arguelles A ^b  

^a CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

^b Laboratorios Clinicos de Puebla   (Mexico)

Author keywords

All trans retinoic acid; Leukaemia; Molecular; Promyelocytic

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; PREDNISONE; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ADULT; ARTICLE; AUTOGRAFT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; REMISSION INDUCTION; RNA, MESSENGER; RNA, NEOPLASM; TREATMENT OUTCOME; TRETINOIN; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELLS;

EID: 0031863716     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.1998.00107.x     Document Type: Article

References (23)

1. Biondi A., Rambaldi A., Pandolfi P.P. et al. (1992) Molecular monitoring of the myl/retinoic acid receptor alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 80, 492-497.
2. Chomczynski P. & Sacchi N. (1987) Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 162, 156-159.
3. De Thé H., Lavau C., Marchio A. et al. (1991) The PML/RAR-α fusion mRNA generated by the t (15; 17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66, 675.
4. Grignani F., Fagioli M., Alcalay M. et al. (1994) Acute promyelocytic leukemia: From genetics to treatment. Blood 83, 10-25.
5. Huang M.E., Ye Y.C. & Chen S.R. (1987) All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukaemia. Report of 6 cases. Chinese Medical Journal 100, 949-953.
6. Kakizuka A., Miller W.H., Umesono K. et al. (1991) Chromosomal translocation t (15; 17) in acute promyelocytic leukemia fuses RAR-α with a novel putative transcription factor PML. Cell 66, 663.
7. Lo Coco F., Diverio D., Pandolfi P.P. et al. (1992) Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 340, 1437-1439.
8. Miller W.J.R., Kakizuka A. & Frankel S.R. (1992) Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America 89, 2694.
9. Miller W.H., Levine K., deBlasio A., Frankel S.R., Dmitrovsky E. & Warrel R.P. Jr (1993) Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 82, 1689-1694.
10. Rubio-Borja M.E., Ovilla-Martínez, R., Labardini J. et al. (1994) All-trans retinoic acid for acute promyelocytic leukemia: toxicity and survival in de novo patients. Blood 84 (Suppl. 1), 147a.
11. Ruiz-Argüelles A. (1992) Flow cytometry in the clinical laboratory. Principles, Applications And Problems. Annals De Biologie Clinique 50, 735-743.
12. Ruiz-Argüelles G.J. (1995) Leucemias agudas. In Ruiz-Argüelles GJ (ed.): Fundamentos de Hematología. Editorial Médica Panamericana. México City, pp. 137-145.
13. Ruiz-Argüelles G.J. (1997) Promyelocytic leukemia in Mexican mestizos. Blood 89, 348-349.
14. Ruiz-Argüelles G.J., Apreza-Molina M.G., Alemán-Hoey D.D., Gómez-Almaguer D., Marín-López A. & Mercado-Díaz L. (1995a) Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: a multicentre study. European Journal of Haematology 54, 18-20.
15. Ruiz-Argüelles A., Duque R.E. & Orfao A. (1997) Informe de la primera conferencia latinomericana de consenso para la tipificación inmunológica de las leucemias. Revista de Investigación Clínica de México 49, 317-322.
16. Ruiz-Argülles G.J., Garcés-Eisele J. & Ruiz-Argüelles A. (1995) ATRA-induced gingival infiltration: report of a case. American Journal of Hematology 49, 364-365.
17. Ruiz-Argüelles G.J., Garcés-Eisele J. & Ruiz-Argüelles A. (1996) Continued complete remission after a PML / RAR-α positive autograft in acute promyelocytic leukaemia. European Journal of Haematology 56, 186-187.
18. Ruiz-Argüelles G.J., Ruiz-Argüelles A., Pérez-Romano B., Marín-López A., Larregina-Díez A. & Apreza-Molina M.G. (1995b) Filgrastim-mobilized peripheral-blood stem cells can be stored at 4 degrees and used in autografts to rescue high-dose chemotherapy. American Journal of Hematology 48, 100-103.
19. San-Miguel J.F. & Duque R. (1996) Utilidad del inmunofenotipo en el diagnóstico y clasificación de las leucemias agudas. In Ruiz-Argüelles GJ. San-Miguel J.F (eds), Actualización En Leucemias. Editorial Médica Panamericana. México City, pp. 25-34.
20. Seale J., Varma S., Swirsky D., Goldman J. & Cross N. (1997) Quantification of the PML/RAR-α fusion mRNA in acute promyelocytic leukemia: quality control of procedures used for the detection if minimal residual disease. British Journal of Haematology 97 (Suppl. 1), 51.
21. Turhan A.G., Lemoine F.M., Debert C. et al. (1995) Highly purified primitive hematopoietic stem cells are PML/RAR-α negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood 85, 2154-2161.
22. Warrel R.P. Jr (1996) Pathogenesis and management of acute promyelocytic leukemia. Annual Review of Medicine 47, 555-565.
23. Warrel R.P. Jr, Maslak P. & Eardley A. (1994) Treatment of acute promyelocytic leukaemia with ATRA: An update of the New York experience. Leukaemia 8, 929-933.